

1999

L1 845 S DIVALPROEX OR VALPORIC OR MIRTAZAPINE  
L2 13362 S OLANZAPINE OR CLOZAPINE OR RISPERIDONE OR QUETIAPINE  
L3 38149 S NIZATIDINE OR CIMETIDINE OR FAMOTIDINE OR RANITIDINE  
L4 1 S L1 (P) L2 (P) L3  
L5 3 S L1 AND L2 AND L3  
L6 376861 S WEIGHT (P) (GAIN OR REDUC? OR EXCESS)  
L7 1 S L1 AND L2 AND L6  
L8 28 S L6 AND L1  
L9 13362 S L2 AND L2  
L10 74 S L9 AND L3  
L11 228 S L2 AND L6  
L12 11 S L11 AND L3  
L13 38 S L8 OR L12  
L14 29 DUPLICATE REMOVE L13 (9 DUPLICATES REMOVED)  
L15 62682 S WEIGHT (5W) (GAIN OR REDUCTION)  
L16 1 S PSYCOTH? AND L15  
L17 1 S L1 AND L2 AND L3 AND L15  
L18 25 S L15 AND L1  
L19 1 S L18 AND L2  
L20 1 S L18 AND L3  
L21 16 DUPLICATE REMOVE L18 (9 DUPLICATES REMOVED)  
L22 41 S L2 (P) L3  
L23 29 DUPLICATE REMOVE L22 (12 DUPLICATES REMOVED)  
L24 18 S ANTIPSYCHOT? (10W) HISTAMINE  
L25 14 DUPLICATE REMOVE L24 (4 DUPLICATES REMOVED)  
L26 3 S L15 AND L24  
L27 1 DUPLICATE REMOVE L26 (2 DUPLICATES REMOVED)  
L28 75 S MOOD (5W) STAB? (5W) (AGENT OR DRUG OR MEDICATION)  
L29 0 S L28 AND L3  
L30 0 S L28 AND HISTAMINE  
L31 5 S L28 AND L1  
L32

L1 20 S (DRUG OR MEDICATION) (5W) INDUCED (5W) (WEIGHT GAIN)  
L2 13 DUPLICATE REMOVE L1 (7 DUPLICATES REMOVED)  
L3 3 S L2 AND ANTIPSYCHOT?  
L4 12 S (OLANZAPINE# OR CLOZAPINE# OR RISPERIDONE OR QUETIAPINE OR  
VA  
L5 0 S L4 AND (ANTIHISTAMINE? OR NIZATIDINE OR FAMOTIDINE OR CIMETI  
L6 8 DUPLICATE REMOVE L4 (4 DUPLICATES REMOVED)  
L7 8 S L6 NOT L3

=> s antipsychot? or olanzapine or clozapine or risperidone or quetiapine

L8 39559 ANTIPSYCHOT? OR OLANZAPINE OR CLOZAPINE OR RISPERIDONE OR  
QUETIA  
PINE

=> s valproic or diavalproex or mirtazapine

L9 21441 VALPROIC OR DIAVALPROEX OR MIRTAZAPINE

=> s antihistamin? or nizatidine or cimetidine or famotidine or ranitidine or  
pepcid or tagamet or axid or zantac

L10 81799 ANTIHISTAMIN? OR NIZATIDINE OR CIMETIDINE OR FAMOTIDINE OR  
RANIT  
IDINE OR PEPCID OR TAGAMET OR AXID OR ZANTAC

=> s histamine (3w) 2 (3w) blocker

L11 62 HISTAMINE (3W) 2 (3W) BLOCKER

=> s histamine (3w) 2 (3w) blocker?

L12 133 HISTAMINE (3W) 2 (3W) BLOCKER?

=> s l12 or l10

L7 ANSWER 1 OF 8 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.  
ACCESSION NUMBER: 1999282473 EMBASE  
TITLE: Risperidone-induced hepatotoxicity in children and adolescents? A chart review study.  
AUTHOR: Szigethy E.; Wiznitzer M.; Branicky L.A.; Maxwell K.; Findling R.L.  
CORPORATE SOURCE: Dr. R.L. Findling, Div. of Child/Adolescent Psychiat., University Hospitals of Cleveland, 11100 Euclid Avenue, Cleveland, OH 44106, United States  
SOURCE: Journal of Child and Adolescent Psychopharmacology, (1999) 9/2 (93-98).  
Refs: 22  
ISSN: 1044-5463 CODEN: JADPET  
COUNTRY: United States  
DOCUMENT TYPE: Journal; Article  
FILE SEGMENT: 007 Pediatrics and Pediatric Surgery  
032 Psychiatry  
048 Gastroenterology  
LANGUAGE: English  
SUMMARY LANGUAGE: English

L7 ANSWER 2 OF 8 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.  
ACCESSION NUMBER: 1998186986 EMBASE  
TITLE: **Olanzapine-induced weight gain.**  
AUTHOR: Gupta S.; Droney T.; Al-Samarrai S.; Keller P.; Frank B.  
CORPORATE SOURCE: Dr. S. Gupta, Research and Education Division, Psychiatric Network, 2221 West State Street, Olean, NY 14760, United States  
SOURCE: Annals of Clinical Psychiatry, (1998) 10/1 (39).  
Refs: 5  
ISSN: 1040-1237 CODEN: APSYEZ  
COUNTRY: United States  
DOCUMENT TYPE: Journal; Article  
FILE SEGMENT: 032 Psychiatry  
037 Drug Literature Index  
038 Adverse Reactions Titles  
LANGUAGE: English

L7 ANSWER 3 OF 8 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.  
ACCESSION NUMBER: 95373238 EMBASE  
DOCUMENT NUMBER: 1995373238  
TITLE: Weight gain induced by clozapine.  
AUTHOR: Hummer M.; Kemmler G.; Kurz M.; Kurzthaler I.; Oberbauer H.; Fleischhacker W.W.  
CORPORATE SOURCE: Department of Biological Psychiatry, Innsbruck University Clinics, Anichstrasse 35,A-6020 Innsbruck, Austria  
SOURCE: European Neuropsychopharmacology, (1995) 5/4 (437-440).  
ISSN: 0924-977X CODEN: EURNE8  
COUNTRY: Netherlands  
DOCUMENT TYPE: Journal; Article  
FILE SEGMENT: 032 Psychiatry  
037 Drug Literature Index  
038 Adverse Reactions Titles  
LANGUAGE: English  
SUMMARY LANGUAGE: English

L7 ANSWER 4 OF 8 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.  
ACCESSION NUMBER: 92030522 EMBASE

DOCUMENT NUMBER: 1991030522  
TITLE: **Clozapine-induced weight gain: Prevalence and clinical relevance.**  
AUTHOR: Leadbetter R.; Shetty M.; Pavalonis D.; Vieweg V.; Higgins P.; Downs M.  
CORPORATE SOURCE: Western State Hospital, P.O. Box 2500, Staunton, VA 24401, United States  
SOURCE: American Journal of Psychiatry, (1992) 149/1 (68-72).  
ISSN: 0002-953X CODEN: AJPSAO  
COUNTRY: United States  
DOCUMENT TYPE: Journal; Conference Article  
FILE SEGMENT: 032 Psychiatry  
037 Drug Literature Index  
038 Adverse Reactions Titles  
LANGUAGE: English  
SUMMARY LANGUAGE: English

L7 ANSWER 5 OF 8 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 91007394 EMBASE

DOCUMENT NUMBER: 1991007394

TITLE: **Clozapine-induced weight gain (Reply).**

AUTHOR: Cohen S.; Chiles J.; MacNaughton A.

SOURCE: American Journal of Psychiatry, (1990) 147/12 (1694).  
ISSN: 0002-953X CODEN: AJPSAO

COUNTRY: United States

DOCUMENT TYPE: Journal; Letter

FILE SEGMENT: 032 Psychiatry  
037 Drug Literature Index  
038 Adverse Reactions Titles

LANGUAGE: English

L7 ANSWER 6 OF 8 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 91007393 EMBASE

DOCUMENT NUMBER: 1991007393

TITLE: **Clozapine-induced weight gain (II).**

AUTHOR: Carson W.H.; Forbes R.A.

SOURCE: American Journal of Psychiatry, (1990) 147/12 (1694).  
ISSN: 0002-953X CODEN: AJPSAO

COUNTRY: United States

DOCUMENT TYPE: Journal; Letter

FILE SEGMENT: 032 Psychiatry  
037 Drug Literature Index  
038 Adverse Reactions Titles

LANGUAGE: English

L7 ANSWER 7 OF 8 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 91007392 EMBASE

DOCUMENT NUMBER: 1991007392

TITLE: **Clozapine-induced weight gain (I).**

AUTHOR: Leadbetter R.A.; Vieweg V.

SOURCE: American Journal of Psychiatry, (1990) 147/12 (1693-1694).  
ISSN: 0002-953X CODEN: AJPSAO

COUNTRY: United States

DOCUMENT TYPE: Journal; Letter

FILE SEGMENT: 032 Psychiatry  
037 Drug Literature Index  
038 Adverse Reactions Titles

LANGUAGE: English

L7 ANSWER 8 OF 8 MEDLINE

ACCESSION NUMBER: 91058215 MEDLINE

DOCUMENT NUMBER: 91058215

TITLE: **Clozapine-induced weight**

TI Novel antipsychotics: Comparison of **weight gain** liabilities.

AB. . . We performed a retrospective analysis of 122 clinical records of 92 male patients with DSM-III-R schizophrenia to examine the relative **weight gain** liabilities of **clozapine**, **risperidone**, **olanzapine**, and sertindole compared with haloperidol. We hypothesized that the unique pharmacodynamic profiles of these agents would contribute to different amounts and patterns of **weight gain**. Method: Data were analyzed to determine differences in **weight gain** during treatment among patients receiving 5 different drug treatments (**clozapine** (N = 20), **olanzapine** (N = 13), **risperidone** (N = 38), haloperidol (N = 43), and sertindole (N = 8)). Measures of maximal **weight gain**, final **weight**, and duration to maximal **weight gain** were calculated. Results: Repeated measures analyses of variance controlling for age, treatment duration, and

initial weight revealed statistically significant differences between groups on all 3 measures. **Clozapine** and **olanzapine** had the greatest maximal weight gain liability (F = 4.13, df = 4,23; p = .01). **Weight gain** with **clozapine**, but not **olanzapine** or **risperidone**, appears to persist (as reflected by final weight) despite behavioral interventions (e.g., nutritional consultation, suggested exercise regimen; F = 5.69, df = 4,23; p = .003). **Clozapine**- and **olanzapine**-treated subjects appeared to gain weight over a prolonged period of time, whereas **risperidone**- and sertindole-treated subjects had a more limited period of **weight gain** (F = 2.95, df = 4,25; p = .04). Conclusion: **Clozapine** and **olanzapine** caused the most **weight gain**, **risperidone** was intermediate, and sertindole had less associated **weight gain** than haloperidol. The relative receptor affinities of the novel antipsychotics for histamine H1 appear to be the most robust correlate of these clinical findings.

IT Major Concepts

Pharmacology; Psychiatry (Human Medicine, Medical Sciences)

IT Diseases

schizophrenia: behavioral and mental disorders

IT Chemicals & Biochemicals

**clozapine**: antipsychotic - drug, side effects, pharmacodynamics; haloperidol: antipsychotic - drug, pharmacodynamics, side effects; **olanzapine**: antipsychotic - drug, pharmacodynamics, side effects; **risperidone**: antipsychotic - drug, side effects, pharmacodynamics; sertindole: antipsychotic -

drug,

pharmacodynamics, side effects

IT Alternate Indexing

Schizophrenia (MeSH)

IT Methods & Equipment

Diagnostic and Statistical Manual of Mental Disorders-III-Revised [DSM-III-R]: diagnostic method

IT Miscellaneous Descriptors

**weight gain**: drug-related

RN 5786-21-0 (**CLOZAPINE**)

52-86-8 (**HALOPERIDOL**)

132539-06-1 (**OLANZAPINE**)

106266-06-2 (**RISPERIDONE**)

106516-24-9 (SERIAL DOLE)  
ACCESSION NUMBER: 106516-24-9:390455 BIOSIS  
DOCUMENT NUMBER: PREV199900390455  
TITLE: Novel antipsychotics: Comparison of **weight**  
**gain** liabilities.  
AUTHOR(S): Wirshing, Donna A. (1); Wirshing, William C.; Kysar, Lisa;  
Berisford, M. Andrew; Goldstein, Danielle; Pashdag,  
Joanna;  
Mintz, Jim; Marder, Stephen R.  
CORPORATE SOURCE: (1) V.A. Greater Los Angeles Healthcare System, 11301  
Wilshire Blvd. (B151-H), Building 210B, Room 15, Los  
Angeles, CA, 90073 USA  
SOURCE: Journal of Clinical Psychiatry, (June, 1999) Vol. 60, No.  
6, pp. 358-363.  
ISSN: 0160-6689.  
DOCUMENT TYPE: Article  
LANGUAGE: English  
SUMMARY LANGUAGE: English

gain [letter; comment].  
COMMENT: Comment on: Am J Psychiatry 1990 Apr;147(4):503-4  
AUTHOR: Anonymous  
SOURCE: AMERICAN JOURNAL OF PSYCHIATRY, (1990 Dec) 147 (12)  
1693-4.  
Journal code: 3VG. ISSN: 0002-953X.  
PUB. COUNTRY: United States  
Commentary  
Letter  
LANGUAGE: English  
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals  
ENTRY MONTH: 199103

=> d kwic 1-4

L7 ANSWER 1 OF 8 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.  
AB . . . drug that has been used in the treatment of numerous psychiatric disorders in children and adolescents. The question of whether **risperidone-induced weight gain** is associated with steatohepatitis has recently been raised. The purpose of this chart review was to ascertain: (1) the rate. . .

L7 ANSWER 2 OF 8 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.  
TI **Olanzapine-induced weight gain.**

L7 ANSWER 3 OF 8 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.  
AB Patients were investigated to gain more insight into the incidence and time course of **clozapine induced weight gain** (n = 81) and to compare weight gain in patients treated with clozapine (n = 31) with that of patients. . .

L7 ANSWER 4 OF 8 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.  
TI **Clozapine-induced weight gain:**  
Prevalence and clinical relevance.

=> d kwic 5-8

L7 ANSWER 5 OF 8 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.  
TI **Clozapine-induced weight gain**  
(Reply).

L7 ANSWER 6 OF 8 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.  
TI **Clozapine-induced weight gain**  
(II).

L7 ANSWER 7 OF 8 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.  
TI **Clozapine-induced weight gain** (I).

L7 ANSWER 8 OF 8 MEDLINE  
TI **Clozapine-induced weight gain**  
[letter; comment].

L9 ANSWER 4 OF 4 CAPLUS COPYRIGHT 1999 ACS  
 AN 1998:147223 CAPLUS  
 DN 128:208924  
 TI Pharmaceutical compositions containing anticonvulsants and NMDA receptor antagonists for treating neuropathic pain  
 IN Caruso, Frank S.; Minn, Fredrick L.; Lyle, John W.  
 PA Algos Pharmaceutical Corporation, USA; Caruso, Frank S.; Minn, Fredrick L.; Lyle, John W.  
 SO PCT Int. Appl., 20 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9807447	A1	19980226	WO 1997-US14680	19970821
	W:		AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG		
	AU 9740788	A1	19980306	AU 1997-40788	19970821
	EP 942752	A1	19990922	EP 1997-938475	19970821
	R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI		
PRAI	US 1996-24508		19960823		
	WO 1997-US14680		19970821		

=> d.kwic 4

L9 ANSWER 4 OF 4 CAPLUS COPYRIGHT 1999 ACS  
 IT 50-06-6, Phenobarbital, biological studies 50-11-3, Metharbital  
 50-12-4, Mephentyoin 57-41-0, Diphenylan 59-66-5, Acetazolamide  
 61-56-3, Sulthiame 63-98-9, Phenacemide 77-41-8, Methsuximide  
 77-67-8, Ethosuximide 86-34-0, Phensuximide 86-35-1, Ethotoin  
 99-66-1, Valproic acid 103-90-2, Acetaminophen 115-38-8,  
 Mephobarbital  
 115-67-3, Paramethadione 125-33-7, Primidone 125-71-3,  
 Dextromethorphan 125-73-5, Dextrorphan 127-48-0, Trimethadione  
 298-46-4, Carbamazepine 630-93-3 768-94-5, Amantadine 1069-66-5,  
 Valproate sodium 1622-61-3, Clonazepam 4350-09-8, L-5-  
 Hydroxytryptophan 7487-88-9, Magnesium sulfate, biological studies  
 12794-10-4, Benzodiazepine 19982-08-2, Memantine 22316-47-8, Clobazam  
 60142-96-3, Gabapentin 62666-20-0, Progabide 76584-70-8,  
**Divalproex** sodium 76824-35-6, **Famotidine** 84057-84-1,  
 Lamotrigine 97240-79-4, Topiramate  
 RL: BAC (Biological activity or effector, except adverse); THU  
 (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (pharmaceutical comps. contg. anticonvulsants and NMDA receptor  
 antagonists for treating neuropathic pain)



FILE 'USPATFULL, CAPLUS, BIOSIS' ENTERED AT 18:05:28 ON 19 NOV 1999

L1	10 S OLANZAPINE AND (FAMOTIDINE OR CIMETIDINE)
L2	9 DUPLICATE REMOVE L1 (1 DUPLICATE REMOVED)
L3	6 S L1 AND (COMBINATION OR MIXTURE)
L4	14 S RISPERIDONE AND (CIMETIDINE OR FAMOTIDINE)
L5	14 DUPLICATE REMOVE L4 (0 DUPLICATES REMOVED)
L6	0 S QUETIAPNE AND (FAMOTIDINE OR CIMETIDINE)
L7	1 S QUETIAPINE AND (FAMOTIDINE OR CIMETIDINE)
L8	2 S MIRTAZAPINE AND (CIMETIDINE OR FAMOTIDINE)
L9	4 S DIVALPROEX AND (FAMOTIDINE OR CIMETIDINE OR NIZATIDINE)

L3 ANSWER 2 OF 6 USPATFULL

ACCESSION NUMBER: 1999:58919 USPATFULL

TITLE: Acylated cyclodextrin-containing pharmaceutical composition

INVENTOR(S): Uekama, Kaneto, Kumamoto, Japan  
Hirayama, Fumitoshi, Kumamoto, Japan  
Kondo, Akira, Shizuoka-ken, Japan  
Ohta, Masaaki, Shizuoka-ken, Japan  
Okamoto, Yasuhiro, Shizuoka-ken, Japan  
Kunihiro, Haruo, Tokyo, Japan

PATENT ASSIGNEE(S): Janssen Pharmaceutica, N.V., Beerse, Belgium (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5904929	19990518
APPLICATION INFO.:	US 1997-886934	19970702 (8)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Schenkman, Leonard	
LEGAL REPRESENTATIVE:	Appollina, Mary A.	
NUMBER OF CLAIMS:	2	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 3 Drawing Page(s)	
LINE COUNT:	574	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 14 USPATFULL  
AN 1999:39960 USPATFULL  
TI Non-polymeric sustained release delivery system  
IN Dunn, Richard L., Fort Collins, CO, United States  
PA Atrix Laboratories, Inc., Fort Collins, CO, United States (U.S.  
corporation)  
PI US 5888533 19990330  
AI US 1997-975765 19971121 (8)  
RLI Continuation of Ser. No. US 1995-549414, filed on 27 Oct 1995, now  
patented, Pat. No. US 5736152  
DT Utility  
LN.CNT 1092  
INCL INCLM: 424/423.000  
INCLS: 424/426.000  
NCL NCLM: 424/423.000  
NCLS: 424/426.000  
IC [6]  
ICM: A61F002-02  
EXF 424/423; 424/426

L5 ANSWER 6 OF 14 CAPLUS COPYRIGHT 1999 ACS  
 AN 1999:404825 CAPLUS  
 DN 131:63471  
 TI Oral delivery drug formulation prepared as flakes  
 IN Compton, Bruce Jon; Solari, Nancy E.; Flanagan, Margaret A.  
 PA Axia Therapeutics, Inc., USA  
 SO PCT Int. Appl., 95 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9930690	A1	19990624	WO 1998-US26627	19981215
	W:				
	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,				
	DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,				
	KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,				
	MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,				
	TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU,				
	TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,				
	FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,				
	CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9918277	A1	19990705	AU 1999-18277	19981215
PRAI	US 1997-69501		19971215		
	US 1998-73867		19980204		
	US 1998-55163		19980404		
	US 1998-55560		19980406		
	US 1997-PV69501		19971215		
	US 1998-PV73867		19980204		